Stockscreener 앱 받기
64.72
0.00%
0.00
시간 외 거래:
64.72
Anaptysbio Inc 주식(ANAB)의 최신 뉴스
Aug Levels: Does AnaptysBio Inc stock have upside surprise potential2026 Recap & Low Drawdown Investment Strategies - baoquankhu1.vn
ANAB Rating Boost: UBS Raises Price Target to $90 | ANAB Stock N - GuruFocus
UBS Group Issues Positive Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat
UBS raises AnaptysBio stock price target to $90 on pipeline upside - Investing.com
AnaptysBio, Inc. $ANAB Shares Purchased by Granahan Investment Management LLC - MarketBeat
AnaptysBio Hits New 12-Month High - National Today
How (ANAB) Movements Inform Risk Allocation Models - Stock Traders Daily
AnaptysBio (NASDAQ:ANAB) Hits New 12-Month HighShould You Buy? - MarketBeat
AnaptysBio stock hits 52-week high at 66.73 USD By Investing.com - Investing.com Australia
Psoriasis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | AnaptysBio, Nimbus Lakshmi, Takeda, MoonLake Immunotherapeutics, Can-Fite Biopha - Barchart
AnaptysBio stock hits 52-week high at 66.73 USD - Investing.com
Adaptive Biotechnologies (ADPT) Rises 5.8%: Can This Momentum Continue? - Bitget
First Light Asset Management Reduces Stake in AnaptysBio - National Today
First Light Asset Management LLC Sells 2,549,432 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
HC Wainwright & Co. Maintains AnaptysBio (ANAB) Buy Recommendation - MSN
Aug Fed Impact: Can AnaptysBio Inc grow without external funding2026 Selloffs & Weekly Chart Analysis and Guides - baoquankhu1.vn
AnaptysBio (ANAB): Wedbush Raises Price Target to $75 with Outpe - GuruFocus
Wedbush Forecasts Strong Price Appreciation for AnaptysBio (NASDAQ:ANAB) Stock - MarketBeat
AnaptysBio Details First Tracks Bio Spin-Off, Jemperli Royalty Surge and GSK Litigation Timeline - MarketBeat
AnaptysBio (NASDAQ:ANAB) Sets New 52-Week HighWhat's Next? - MarketBeat
AnaptysBio Plans First Tracks Spin-Off as Jemperli Royalties Surge, Buybacks Possible - MarketBeat
Barclays Initiates Coverage of AnaptysBio (ANAB) with Overweight Recommendation - MSN
ANAB: Biopharma spin-off advances antibody pipeline as royalty business leverages Jemperli growth - TradingView
ANAB: Truist Securities Maintains Hold Rating, Raises Price Targ - GuruFocus
AnaptysBio, Inc. $ANAB Shares Sold by Citigroup Inc. - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
AnaptysBio, Inc. Experiences Revision in Its Stock Evaluation Amid Market Trends - Markets Mojo
Truist raises AnaptysBio stock price target to $50 on Jemperli outlook - Investing.com Canada
Truist Adjusts Price Target on AnaptysBio to $50 From $36, Maintains Hold Rating - marketscreener.com
What is HC Wainwright's Estimate for AnaptysBio Q1 Earnings? - MarketBeat
Assessing AnaptysBio (ANAB) Valuation After Profitability Turnaround And Strong Jemperli Royalty Progress - Yahoo Finance
AnaptysBio (ANAB) Q4 Profit Of US$49.6 Million Tests Longstanding Loss-Making Narrative - Sahm
Trading Systems Reacting to (ANAB) Volatility - Stock Traders Daily
AnaptysBio stock hits 52-week high at 57.86 USD By Investing.com - Investing.com Nigeria
HC Wainwright Weighs in on AnaptysBio FY2030 Earnings - MarketBeat
AnaptysBio, Inc. Hits New 52-Week High of $62.69, Up 156% - Markets Mojo
AnaptysBio Stock Soars 14.61%, Hits Intraday High of $62.69 - Markets Mojo
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $85.00 at Stifel Nicolaus - MarketBeat
Stifel Raises Price Target for AnaptysBio (ANAB) to $85, Reaffir - GuruFocus
AnaptysBio stock hits 52-week high at 57.86 USD - Investing.com South Africa
AnaptysBio Says R&D Spinout May Launch By April - Citeline News & Insights
AnaptysBio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
AnaptysBio Details Plan to Split Into RoyaltyCo and Biopharma at TD Cowen Healthcare Conference - MarketBeat
Barclays Raises AnaptysBio Price Target to $79 - National Today
AnaptysBio Hits New 52-Week High After Analyst Upgrade - National Today
AnaptysBio (NASDAQ:ANAB) Hits New 52-Week High Following Analyst Upgrade - MarketBeat
ANAB: Barclays Raises Price Target to $79, Maintains Overweight Rating | ANAB Stock News - GuruFocus
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $79.00 - MarketBeat
HC Wainwright Raises AnaptysBio (NASDAQ:ANAB) Price Target to $66 - National Today
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $66.00 at HC Wainwright - MarketBeat
H.C. Wainwright raises AnaptysBio stock price target to $66 By Investing.com - Investing.com Canada
Wedbush Raises Price Target on AnaptysBio to $60 From $50, Keeps Outperform Rating - marketscreener.com
AnaptysBio Swings To Q4 Profit, Narrows FY25 Loss; Spin-Off Of Biopharma Operations In Q2 2026 - Nasdaq
HC Wainwright & Co. Raises Price Target and Maintains Buy Rating for ANAB | ANAB Stock News - GuruFocus
H.C. Wainwright raises AnaptysBio stock price target to $66 - Investing.com UK
AnaptysBio (ANAB) PT Raised to $66 at H.C. Wainwright - StreetInsider
GSK's Biopharma Collaborations Highlighted in AnaptysBio Spin-Of - GuruFocus
Beyond the Balance Sheet: What SWOT Reveals About AnaptysBio Inc (ANAB) - GuruFocus
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results - Bitget
AnaptysBio, Inc. (ANAB) Q4 Earnings and Revenues Top Estimates - Bitget
1.20%
0.06%
자본화:
|
볼륨(24시간):